Bellerophon Stock Surges After Positive Data From Sarcoidosis-Associated Pulmonary Hypertension Trial

Bellerophon Therapeutics Inc BLPH shares are trading higher after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart catheterization for pulmonary hypertension associated with sarcoidosis (PH-Sarc).

• Sarcoidosis is characterized by the growth of small collections of inflammatory cells (granulomas) in any part of the body, most commonly the lungs and lymph nodes. 
• All eight subjects demonstrated decreases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) across the doses of INOpulse utilized in the study.
• The dose of iNO45 (45 mcg/kg IBW/hr) resulted in a median drop of 20% in PVR, compared to a median baseline PVR of 329 dyne/cm.
• The highest dose of iNO125 (125 mcg/kg IBW/hr) demonstrated further improvement in PVR, with a median drop of 29%, achieving statistical significance from baseline and the preceding lower dose of iNO75 (75 mcg/kg IBW/hr). 
• During the study, 7 out of 8 patients escalated to the highest dose, iNO125.
• mPAP decreased by a median of 6-10% across the doses of iNO30 to iNO125, compared to a median baseline mPAP of 37.2 mmHg.
• No treatment-emergent adverse events or serious adverse events occurred.
• Price Action: BLPH shares are up 44.7% at $3.45 during the market session on the last check Friday.